Guo Xufeng
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma (NCT06056336) | Guo Xufeng | 2023-09-07 |
Track Guo Xufeng automatically
Every clearance here is in the API, with alerts when new ones post.